160 D.W. End et al. References 1. Quesney-Huneeus V, Wiley MH, Siperstein MD (1979) Proc Natl Acad Sci USA 76:5056 2. Habenicht AJ, Glomset JA, Ross R (1980) J Biol Chem 255:5134 3. Schmidt RA, Schneider CJ, Glomset JA (1984) J Biol Chem 259:10175 4. Beck LA, Hosick TJ, Sinensky M (1988) J Cell Biol 107:1307 5. Casey PJ, Solski PA, Der CJ, Buss J (1989) Proc Natl Acad Sci USA 86:832 6. Leonard S, Beck L, Sinensky M (1990) J Biol Chem 265:5157 7. Barbacid M (1987) Ann Rev Biochem 56:779 8. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ (1992) Proc Natl Acad Sci USA 89:6403 9. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ (1990) Proc Natl Acad Sci USA 87:3042 10. Sinensky M, Beck LA, Leonard S, Evans R (1990) J Biol Chem 265:19937 11. Gibbs JB (1991) Cell 65:1 12. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS (1990) Cell 62:81 13. Cox AD, Der CJ (1997) Biochim Biophys Acta 1333:F51 14. Zujewski J, Horak ID, Woestenborghs R, Chiao J, Cusack G, Kohler D, Kremer AB, Cowan KH (1998) Proc Am Assoc Cancer Res 39:270 15. Hudes GR, Schol J, Baab J, Rogatko A, Bol C, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ, Weiner L (1999) Proc Am Soc Clin Oncol 18:601 16. Adjei AA, Erlichman C, Davis JN, Reid J, Sloan J, Statkevich P, Zhu Y, Marks RS, Pitot HC, Goldberg R, Hanson L, Alberts S, Cutler D, Kaufman SH (1999) Proc Am Soc Clin Oncol 18:598 17. Schellens JHM, De KlerkG, SwartM, PalmerPA, BolCJ, Van’t Veer LJ, TanH, ten Bokkel Huinink WW, Beijnen JH (1999) Proc Am Assoc Cancer Res 40:724 18. Nakagawa K, Yamamoto N, Nishio K, Ohashi Y, End D, Bol Kees, Ito H, Fukuoka M (2001) Proc Am Soc Clin Oncol 20:317 19. Raponi M, Belly RT, Karp JE, Lancet JE, Atkind D, Wang Y (2004) BMC Cancer 4:56 20. RaponiM,ZhangY,JatkoeT,YuJ,LeeG,LancetJE,KarpJE,ThibaultA,WangX (2005) Blood 106:Abstract 2785 21. Maltese WA, Erdman RA (1989) J Biol Chem 264:18168 22. Pompliano DL, Schaber MD, Mosser SD, Omer CA, Shafer JA, Gibbs JB (1993) Biochemistry 32:8341 23. Furfine ES, Leban JJ, Landavazo A, Moomaw JF, Casey PJ (1995) Biochemistry 34:6857 24. StricklandCL, Windsor WT, Syto R, Wang L, Bond R, Wu Z, SchwartzJ, Le HV, Beese LS, Weber PC (1998) Biochemistry 37:16601 25. Yokoyama K, McGeady P, Gelb MH (1995) Biochemistry 34:1344 26. Park HW, Boduluri SR, Moomaw JF, Casey PJ, Beese LS (1997) Science 275:1800 27. Long SB, Casey PJ, Beese LS (1998) Biochemistry 37:9612 28. Dunten P, Kammlott U, Crowther R, Weber D, Palermo R, Birktoft J (1998) Biochemistry 37:7907 29. Huang CC, Casey PJ, Fierke CA (1997) J Biol Chem 272:20 30. Hightower KE, Huang CC, Casey PJ, Fierke CA (1998) Biochemistry 37:15555 31. Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL, Brown MS (1991) J Biol Chem 266:10672 32. Seabra MC, Reiss Y, Casey PJ, Brown MS, Goldstein JL (1991) Cell 65:429 33. Otto JC, Kim E, Young SG, Casey PJ (1999) J Biol Chem 274:8379 34. Gutierrez L, Magee AI, Marshall CJ, Hancock JF (1989) EMBO J 8:1093
Farnesyl Protein Transferase Inhibitors 161 35. Seabra MC, Goldstein JL, Sudhof TC, Brown MS (1992) J Biol Chem 267:14497 36. Seabra MC, Brown MS, Slaughter CA, Sudhof TC, Goldstein JL (1992) Cell 70:1049 37. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA (1993) Nature 363:45 38. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF (1994) Science 264:1463 39. Moodie SA, Willumsen BM, Weber MJ, Wolfman A (1993) Science 260:1658 40. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Science 260:1934 41. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC (1993) Science 260:1937 42. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N (1995) Cancer Res 55:5302 43. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C (2001) Cancer Res 61:131 44. James G, Goldstein JL, Brown MS (1996) Proc Natl Acad Sci USA 93:4454 45. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM (1997) J Biol Chem 272:14093 46.WhyteDB,KirschmeierP,HockenberryTN,Nunez-OlivaI,JamesL,CatinoJJ, Bishop WR, Pai JK (1997) J Biol Chem 272:14459 47. GrunewaldK,LyonsJ,FrohlichA,FeichtingerH,WegerRA,SchwabG,JanssenJW, Bartram CR (1989) Int J Cancer 43:1037 48. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M (1987) Nature 327:298 49. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) N Engl J Med 319:525 50. ReynoldsSH,AnnaCK,BrownKC,WiestJS,BeattieEJ,PeroRW,IglehartJD,Anderson MW (1991) Proc Natl Acad Sci USA 88:1085 51. Knowles MA, Williamson M (1993) Cancer Res 53:133 52. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM (1995) Cancer Res 55:5310 53. Maltese WA (1990) FASEB J 4:3319 54. Sun J, Qian Y, Hamilton AD, Sebti SM (1998) Oncogene 16:1467 55.LobellR,AnthonyN,BellI,BuserC,DesolmsJ,DinsmoreC,GibbsJ,GrahamS, Hartman G, Heimbrook D, Huber H, Lumma W, William T, Kohl N (2001) Proc Am Assoc Cancer Res 42:259 56. Prendergast GC (2001) Histol Histopathol 16:269 57. Hall A (1998) Science 279:509 58. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ (1995) Oncogene 10:2289 59. Adamson P, Marshall CJ, Hall A, Tilbrook PA (1992) J Biol Chem 267:20330 60. Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC, Pradines A (2000) Proc Natl Acad Sci USA 97:11626 61. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA (1997) J Biol Chem 272:15591 62. Du W, Lebowitz PF, Prendergast GC (1999) Mol Cell Biol 19:1831 63. Du W, Prendergast GC (1999) Cancer Res 59:5492 64. Liu AX, Du W, Liu JP, Jessell TM, Prendergast GC (2000) Mol Cell Biol 20:6105 65. Liu AX, Cerniglia GJ, Bernhard EJ, Prendergast GC (2001) Proc Natl Acad Sci USA 98:6192 66. Teyssier F, Dalenc F, Pradines A, Couderc B, Ader I, Bonnet J, Cohen-Jonathan E, Toulas C, Favre G (2001) Proc Am Assoc Cancer Res 42:489 67. Van Golen KL, Bao LW, DiVito MM, Wu ZF, Prendergast GC, Merajver SD (2002) Mol Cancer Ther 1:575
- Page 2 and 3:
1 Topics in Medicinal Chemistry Edi
- Page 4 and 5:
Drug research requires interdiscipl
- Page 6 and 7:
Topics in Medicinal Chemistry Also
- Page 8 and 9:
Preface to Volume 1 With supreme ir
- Page 10 and 11:
Contents Overview R.H.Bradbury ....
- Page 12 and 13:
Top Med Chem (2007) 1: 1-17 DOI 10.
- Page 14 and 15:
Overview 3 led to animal experiment
- Page 16 and 17:
Overview 5 electrodes, an effect la
- Page 18 and 19:
Overview 7 Fig. 3 Acquired capabili
- Page 20 and 21:
Overview 9 Table 3 Marketed targete
- Page 22 and 23:
Overview 11 pathways mediating one
- Page 24 and 25:
Overview 13 Table 4 Targeted drugs
- Page 26 and 27:
Overview 15 10. Brock N (1989) Canc
- Page 28 and 29:
Overview 17 83. Daniel KG, Kuhn DJ,
- Page 30 and 31:
20 J. Hoffmann · A. Sommer with in
- Page 32 and 33:
22 J. Hoffmann · A. Sommer Most ta
- Page 34 and 35:
24 J. Hoffmann · A. Sommer classic
- Page 36 and 37:
26 J. Hoffmann · A. Sommer Fig. 3
- Page 38 and 39:
28 J. Hoffmann · A. Sommer PR is h
- Page 40 and 41:
30 J. Hoffmann · A. Sommer activat
- Page 42 and 43:
32 J. Hoffmann · A. Sommer of ERα
- Page 44 and 45:
34 J. Hoffmann · A. Sommer in brea
- Page 46 and 47:
36 J. Hoffmann · A. Sommer Fig. 7
- Page 48 and 49:
38 J. Hoffmann · A. Sommer cantly
- Page 50 and 51:
40 J. Hoffmann · A. Sommer pared w
- Page 52 and 53:
42 J. Hoffmann · A. Sommer in the
- Page 54 and 55:
44 J. Hoffmann · A. Sommer Fig. 9
- Page 56 and 57:
46 J. Hoffmann · A. Sommer the syn
- Page 58 and 59:
48 J. Hoffmann · A. Sommer ture [1
- Page 60 and 61:
50 J. Hoffmann · A. Sommer isation
- Page 62 and 63:
52 J. Hoffmann · A. Sommer droloxi
- Page 64 and 65:
54 J. Hoffmann · A. Sommer Non-ste
- Page 66 and 67:
56 J. Hoffmann · A. Sommer genic,
- Page 68 and 69:
58 J. Hoffmann · A. Sommer The pur
- Page 70 and 71:
60 J. Hoffmann · A. Sommer cacy of
- Page 72 and 73:
62 J. Hoffmann · A. Sommer Fig. 15
- Page 74 and 75:
64 J. Hoffmann · A. Sommer Neverth
- Page 76 and 77:
66 J. Hoffmann · A. Sommer in the
- Page 78 and 79:
68 J. Hoffmann · A. Sommer been de
- Page 80 and 81:
70 J. Hoffmann · A. Sommer High-do
- Page 82 and 83:
72 J. Hoffmann · A. Sommer Table 1
- Page 84 and 85:
74 J. Hoffmann · A. Sommer Blockin
- Page 86 and 87:
76 J. Hoffmann · A. Sommer 55. Rod
- Page 88 and 89:
78 J. Hoffmann · A. Sommer 122. Hi
- Page 90 and 91:
80 J. Hoffmann · A. Sommer 174. Is
- Page 92 and 93:
82 J. Hoffmann · A. Sommer 234. Go
- Page 94 and 95:
84 E.M. Wallace et al. Abstract App
- Page 96 and 97:
86 E.M. Wallace et al. Fig. 1 Targe
- Page 98 and 99:
88 E.M. Wallace et al. There are th
- Page 100 and 101:
90 E.M. Wallace et al. participates
- Page 102 and 103:
92 E.M. Wallace et al. ture, most o
- Page 104 and 105:
94 E.M. Wallace et al. Fig. 5 The b
- Page 106 and 107:
96 E.M. Wallace et al. 4.1 Selectiv
- Page 108 and 109:
98 E.M. Wallace et al. care or supp
- Page 110 and 111:
100 E.M. Wallace et al. trials. The
- Page 112 and 113:
102 E.M. Wallace et al. in three hu
- Page 114 and 115:
104 E.M. Wallace et al. Table 1 Cel
- Page 116 and 117:
106 E.M. Wallace et al. 4.2.3 ARRY-
- Page 118 and 119:
108 E.M. Wallace et al. HKI-272 inh
- Page 120 and 121: 110 E.M. Wallace et al. crease hepa
- Page 122 and 123: 112 E.M. Wallace et al. respectivel
- Page 124 and 125: 114 E.M. Wallace et al. Fig. 9 Stru
- Page 126 and 127: 116 E.M. Wallace et al. end of this
- Page 128 and 129: 118 E.M. Wallace et al. compound do
- Page 130 and 131: 120 E.M. Wallace et al. 6.2 PD03259
- Page 132 and 133: 122 E.M. Wallace et al. sies, but t
- Page 134 and 135: 124 E.M. Wallace et al. Despite the
- Page 136 and 137: 126 E.M. Wallace et al. are designe
- Page 138 and 139: 128 E.M. Wallace et al. 42. Fabian
- Page 140 and 141: 130 E.M. Wallace et al. Perrier M,
- Page 142 and 143: 132 E.M. Wallace et al. nowski S, O
- Page 144 and 145: 134 D.W. End et al. logical maligna
- Page 146 and 147: 136 D.W. End et al. growth. In part
- Page 148 and 149: 138 D.W. End et al. C-A-A-X recogni
- Page 150 and 151: 140 D.W. End et al. Fig. 3 Structur
- Page 152 and 153: 142 D.W. End et al. Fig. 5 CAAX pep
- Page 154 and 155: 144 D.W. End et al. mediates all of
- Page 156 and 157: 146 D.W. End et al. 3.6 FTase Knock
- Page 158 and 159: 148 D.W. End et al. acid giving a c
- Page 160 and 161: 150 D.W. End et al. Fig. 7 Target d
- Page 162 and 163: 152 D.W. End et al. GTase II. Altho
- Page 164 and 165: 154 D.W. End et al. Fig. 11 Aryl cy
- Page 166 and 167: 156 D.W. End et al. Fig. 14 Structu
- Page 168 and 169: 158 D.W. End et al. ness, Chagas di
- Page 172 and 173: 162 D.W. End et al. 68. Chen Z, Sun
- Page 174 and 175: 164 D.W. End et al. 122. Shaikenov
- Page 176 and 177: 166 D.W. End et al. 156. Dinsmore C
- Page 178 and 179: 168 D.W. End et al. 201. Gelb MH, V
- Page 180 and 181: 170 C. Garcia-Echeverria Keywords H
- Page 182 and 183: 172 C. Garcia-Echeverria 2 Insulin-
- Page 184 and 185: 174 C. Garcia-Echeverria 2.2 Modula
- Page 186 and 187: 176 C. Garcia-Echeverria lesions ar
- Page 188 and 189: 178 C. Garcia-Echeverria the divers
- Page 190 and 191: 180 C. Garcia-Echeverria Fig. 3 Rep
- Page 192 and 193: 182 C. Garcia-Echeverria cal assays
- Page 194 and 195: 184 C. Garcia-Echeverria one within
- Page 196 and 197: 186 C. Garcia-Echeverria Epidemiolo
- Page 198 and 199: 188 C. Garcia-Echeverria Fig. 5 Rep
- Page 200 and 201: 190 C. Garcia-Echeverria allosteric
- Page 202 and 203: 192 C. Garcia-Echeverria Currently,
- Page 204 and 205: 194 C. Garcia-Echeverria 24 h. No i
- Page 206 and 207: 196 C. Garcia-Echeverria Fig. 8 Rep
- Page 208 and 209: 198 C. Garcia-Echeverria Fig. 9 PI3
- Page 210 and 211: 200 C. Garcia-Echeverria References
- Page 212 and 213: 202 C. Garcia-Echeverria 64. Ihle N
- Page 214 and 215: 204 C. Garcia-Echeverria 119. Jones
- Page 216 and 217: 206 C. Garcia-Echeverria 175. Posad
- Page 218 and 219: 208 K.J. Moriarty et al. 3.3.3 Thie
- Page 220 and 221:
210 K.J. Moriarty et al. erodimeric
- Page 222 and 223:
212 K.J. Moriarty et al. inhibitors
- Page 224 and 225:
214 K.J. Moriarty et al. Structure
- Page 226 and 227:
216 K.J. Moriarty et al. K i = 0.00
- Page 228 and 229:
218 K.J. Moriarty et al. Structure
- Page 230 and 231:
220 K.J. Moriarty et al. lectivity
- Page 232 and 233:
222 K.J. Moriarty et al. 2.3.5 3,5-
- Page 234 and 235:
224 K.J. Moriarty et al. A variety
- Page 236 and 237:
226 K.J. Moriarty et al. Fig. 3 Com
- Page 238 and 239:
228 K.J. Moriarty et al. a benefici
- Page 240 and 241:
230 K.J. Moriarty et al. Structure
- Page 242 and 243:
232 K.J. Moriarty et al. Structure
- Page 244 and 245:
234 K.J. Moriarty et al. This compo
- Page 246 and 247:
236 K.J. Moriarty et al. IC 50 = 0.
- Page 248 and 249:
238 K.J. Moriarty et al. Structure
- Page 250 and 251:
240 K.J. Moriarty et al. over CDK1.
- Page 252 and 253:
242 K.J. Moriarty et al. Structure
- Page 254 and 255:
244 K.J. Moriarty et al. with an al
- Page 256 and 257:
246 K.J. Moriarty et al. Fig. 7 Com
- Page 258 and 259:
248 K.J. Moriarty et al. studies, 6
- Page 260 and 261:
250 K.J. Moriarty et al. Structure
- Page 262 and 263:
252 K.J. Moriarty et al. panies. As
- Page 264 and 265:
254 K.J. Moriarty et al. Fig. 10 Di
- Page 266 and 267:
256 K.J. Moriarty et al. Fig. 13 Co
- Page 268 and 269:
258 K.J. Moriarty et al. Structure
- Page 270 and 271:
260 K.J. Moriarty et al. Structure
- Page 272 and 273:
262 K.J. Moriarty et al. (70% inhib
- Page 274 and 275:
264 K.J. Moriarty et al. Structure
- Page 276 and 277:
266 K.J. Moriarty et al. Structure
- Page 278 and 279:
268 K.J. Moriarty et al. Structure
- Page 280 and 281:
270 K.J. Moriarty et al. of DNA syn
- Page 282 and 283:
272 K.J. Moriarty et al. Structure
- Page 284 and 285:
274 K.J. Moriarty et al. 4.3.2 Pyri
- Page 286 and 287:
276 K.J. Moriarty et al. Structure
- Page 288 and 289:
278 K.J. Moriarty et al. Structure
- Page 290 and 291:
280 K.J. Moriarty et al. 4.3.8 3-Et
- Page 292 and 293:
282 K.J. Moriarty et al. 29. Brothe
- Page 294 and 295:
284 K.J. Moriarty et al. 81. Yue EW
- Page 296 and 297:
286 K.J. Moriarty et al. 122. Brams
- Page 298 and 299:
288 K.J. Moriarty et al. Hercend T,
- Page 300 and 301:
290 K.J. Moriarty et al. 229. Esced
- Page 302 and 303:
Top Med Chem (2007) 1: 293-331 DOI
- Page 304 and 305:
HDAC Inhibition in Cancer Therapy 2
- Page 306 and 307:
HDAC Inhibition in Cancer Therapy 2
- Page 308 and 309:
HDAC Inhibition in Cancer Therapy 2
- Page 310 and 311:
HDAC Inhibition in Cancer Therapy 3
- Page 312 and 313:
HDAC Inhibition in Cancer Therapy 3
- Page 314 and 315:
HDAC Inhibition in Cancer Therapy 3
- Page 316 and 317:
HDAC Inhibition in Cancer Therapy 3
- Page 318 and 319:
HDAC Inhibition in Cancer Therapy 3
- Page 320 and 321:
HDAC Inhibition in Cancer Therapy 3
- Page 322 and 323:
HDAC Inhibition in Cancer Therapy 3
- Page 324 and 325:
HDAC Inhibition in Cancer Therapy 3
- Page 326 and 327:
HDAC Inhibition in Cancer Therapy 3
- Page 328 and 329:
HDAC Inhibition in Cancer Therapy 3
- Page 330 and 331:
HDAC Inhibition in Cancer Therapy 3
- Page 332 and 333:
HDAC Inhibition in Cancer Therapy 3
- Page 334 and 335:
HDAC Inhibition in Cancer Therapy 3
- Page 336 and 337:
HDAC Inhibition in Cancer Therapy 3
- Page 338 and 339:
HDAC Inhibition in Cancer Therapy 3
- Page 340 and 341:
HDAC Inhibition in Cancer Therapy 3
- Page 342 and 343:
334 K. Paz · Z. Zhu application of
- Page 344 and 345:
336 K. Paz · Z. Zhu mor cells [33-
- Page 346 and 347:
338 K. Paz · Z. Zhu of vascular in
- Page 348 and 349:
340 K. Paz · Z. Zhu DC101 has been
- Page 350 and 351:
342 K. Paz · Z. Zhu cemia. In Marc
- Page 352 and 353:
344 K. Paz · Z. Zhu but there were
- Page 354 and 355:
346 K. Paz · Z. Zhu effects after
- Page 356 and 357:
348 K. Paz · Z. Zhu adverse effect
- Page 358 and 359:
350 K. Paz · Z. Zhu the first comp
- Page 360 and 361:
352 K. Paz · Z. Zhu detanib doses
- Page 362 and 363:
354 K. Paz · Z. Zhu 3.4.4 Neovasta
- Page 364 and 365:
356 K. Paz · Z. Zhu monotherapy tr
- Page 366 and 367:
358 K. Paz · Z. Zhu 13736), a pote
- Page 368 and 369:
360 K. Paz · Z. Zhu Phase I clinic
- Page 370 and 371:
362 K. Paz · Z. Zhu 3.4.10 BAY57-9
- Page 372 and 373:
364 K. Paz · Z. Zhu stabilization
- Page 374 and 375:
366 K. Paz · Z. Zhu cles. Common a
- Page 376 and 377:
368 K. Paz · Z. Zhu ovary, and fal
- Page 378 and 379:
370 K. Paz · Z. Zhu 6. Creamer D,
- Page 380 and 381:
372 K. Paz · Z. Zhu 73. Sato Y, Ka
- Page 382 and 383:
374 K. Paz · Z. Zhu 132. Takahashi
- Page 384 and 385:
376 K. Paz · Z. Zhu 189. Graeven U
- Page 386 and 387:
378 K. Paz · Z. Zhu Hawtin R, Tang
- Page 388 and 389:
380 K. Paz · Z. Zhu 287. Carlomagn
- Page 390 and 391:
382 K. Paz · Z. Zhu 345. Yu JL, Ra
- Page 392 and 393:
384 T.K. Sawyer Keywords Src · Src
- Page 394 and 395:
386 T.K. Sawyer Table 2 Some functi
- Page 396 and 397:
388 T.K. Sawyer pathways has been l
- Page 398 and 399:
390 T.K. Sawyer nate proteins, and
- Page 400 and 401:
392 T.K. Sawyer Fig. 6 Some known S
- Page 402 and 403:
394 T.K. Sawyer interactions betwee
- Page 404 and 405:
396 T.K. Sawyer collagen type-I-ind
- Page 406 and 407:
398 T.K. Sawyer AP23451 administrat
- Page 408 and 409:
400 T.K. Sawyer ery. This chapter h
- Page 410 and 411:
402 T.K. Sawyer 48. Lutz MP, Esser
- Page 412 and 413:
404 T.K. Sawyer 96. Nimmanapalli R,
- Page 414 and 415:
Top Med Chem (2007) 1: 407-444 DOI
- Page 416 and 417:
Bcr-Abl Kinase Inhibitors 409 2 Ima
- Page 418 and 419:
Bcr-Abl Kinase Inhibitors 411 3 New
- Page 420 and 421:
Bcr-Abl Kinase Inhibitors 413 sista
- Page 422 and 423:
Bcr-Abl Kinase Inhibitors 415 3.1.2
- Page 424 and 425:
Bcr-Abl Kinase Inhibitors 417 Schem
- Page 426 and 427:
Bcr-Abl Kinase Inhibitors 419 Schem
- Page 428 and 429:
Bcr-Abl Kinase Inhibitors 421 group
- Page 430 and 431:
Bcr-Abl Kinase Inhibitors 423 Altho
- Page 432 and 433:
Bcr-Abl Kinase Inhibitors 425 4.4 S
- Page 434 and 435:
Bcr-Abl Kinase Inhibitors 427 of CM
- Page 436 and 437:
Bcr-Abl Kinase Inhibitors 429 both
- Page 438 and 439:
Bcr-Abl Kinase Inhibitors 431 five
- Page 440 and 441:
Bcr-Abl Kinase Inhibitors 433 ity o
- Page 442 and 443:
Bcr-Abl Kinase Inhibitors 435 cal t
- Page 444 and 445:
Bcr-Abl Kinase Inhibitors 437 The l
- Page 446 and 447:
Bcr-Abl Kinase Inhibitors 439 44. M
- Page 448 and 449:
Bcr-Abl Kinase Inhibitors 441 92. h
- Page 450 and 451:
Bcr-Abl Kinase Inhibitors 443 134.
- Page 452 and 453:
Author Index Volume 1 Thevolumenumb
- Page 454 and 455:
Subject Index Abiraterone 50 Ableso
- Page 456 and 457:
Subject Index 449 Hormone response
- Page 458:
Subject Index 451 Testosterone 47,